THE DEVELOPMENT OF A CLINICAL DECISION SUPPORT FOR ILLICIT SUBSTANCE USE IN PRIMARY CARE SETTINGS

8th Annual Conference of INEBRIA September 23, 2011

Acknowledgements

Expert Panel Members

- Rowena Dolor
- David Fiellin
- Jennifer Gierisch
- John March
- Jennifer McNeely
- Andrew Saxon
- Christopher Shanahan
- Jeanette Tetrault
- Roger Weiss

NIDA Staff

Betty Tai Geetha Subramaniam Udi Ghitza

EMMES Consultants

Robert Gore-Langton Robert Lindblad

SAMHSA Partners

Reed Forman Bob Stephenson Kenneth Salyards Tony Calice (OBHITA, FEI systems)

Rational for Screening for SUD in Medical Settings

- Common point of contact for adults
- Opportunity to detect misuse or problem use
- Intervene early in low/mild severity (better outcomes)
- Increase awareness and drug-medication interactions
- O Potentially improve patient adherence
- Cost-benefits of SUD treatment
- Reductions in high cost inpatient costs/repeat ED visits
- Efficacious treatments/interventions are available
- SUD treatment is efficacious in reducing morbidity and negative consequences

States with Screening, Brief Intervention, Referral and Treatment (SBIRT) Programs



screening & brief intervention, 2008 www. WhiteHouseDrugPolicy.gov

Definition of CDS


"Providing clinicians or patients with clinical knowledge and patient-related information, intelligently filtered or presented at appropriate times, to enhance patient care".

- Osheroff JA, Pifer EA, Teich JM, et al. 2005

(Improving Outcomes With Clinical Decision Support: An Implementer's Guide. Chicago, III: HIMSS)

Model: Stages for Screening CDS

Stage 1: Universal or Targeted ScreeningStage 2: Brief AssessmentStage 3: Plan of ActionStage 4: Follow-up




Stage 1: Screening

Administer the 1-item Screener

"How many times in the past year have you used an illegal drug or used a prescription medication for non-medical reasons?"



Smith, P. C., Schmidt, S. M., Allensworth-Davies, D., & Saitz, R. (2010). A single-question screening test for drug use in primary care. Arch Intern Med, 170(13), 1155-1160.



If 1-item Screener score = 0,


Plan of Action for Minimal or No Risk

Provide brief positive feedback

Schedule appt to re-screen at annual visit

If 1-item Screener score > 0

Go to Stage 2 – Brief Assessment



Stage 2: Brief Assessment


Administer DAST -10 questionnaire

Plus

 Ask Drug Type and Frequency of Use Questions


Ask about Injection Drug Use

Ask about SUD Treatment Status



Plan of Action: Low Intensity

Low Intensity Intervention (Level Amber)							
Screening Criteria	DAST-10 Score	0-2					
	and	 No daily use of any substance No weakly use of opioids, cosping, or 					
	Additional Criteria	 No weekly use of opioids, cocaine, or methamphetamine No injection drug use in the past three months Not currently in Drug Abuse Treatment 					
Actions to Consider	remaining dr • Monitor/re months)	e on benefits / importance achieving or rug abstinent assess at next visit (e.g. follow-up within 6 lucational materials					



Determination of High Intensity

High Intensity Determination (Level Red)						
	DAST-10 Score	scores <u>></u> 3				
Screening	Or					
Criteria	DAST-10 Score	0-2				
	and	Daily use of any substance				
	Additional Criteria	 Weekly use of opioids, cocaine, or stimulants Injection drug use in the past three months Currently in Drug Abuse Treatment 				

Plan of Action: High Intensity (Level Red)						
	 Recommend cessation Assess readiness to change Facilitate referral to an addiction specialist/program Encourage self-help group meeting attendance 					
Actions to Consider	 Additional issues to consider: Review current medications Obtain drug abuse treatment history Order urine drug screen 					

Plan of Action: High Intensity (Level Red continued)

Obtain tobacco and alcohol use history Screen for common mental health conditions Provide preventive health screening Refer for immediate crisis intervention, if needed Schedule 1-month follow-up visit

Actions to Consider

* For patients With Opioid Dependence:

- Initiate on-site/integrated medication-assisted treatment for opioid dependence
 or
- Refer to an outside provider/organization

The Open Behavioral Health Information Technology Architecture

Five year, \$16M program seeking to:

- Simplify and standardize healthcare standards for the behavioral health community
- Make Health Information Technology (HIT) accessible to Behavioral Health & Primary Care

BHITA.ORG

 Implement a Reference Electronic Health Record Model (REM) Screen Shot: 1item Screener

One-time Screener

How many times in the past year have you used an illegal drug or used a prescription medication for non-medical reasons?

Screen Shot: Visit Note for Minimal or No Risk Patient


Visit Note 09/20/2011

Summary:

Your patient indicated that they:

Have not used an illegal drug nor used a prescription medication for nonmedical reasons

Actions to Consider:



Re-screen at next annual visit 09/01/2012

Patient Resources

Produce Summary for Patient

e

Link to billing Procedure Code

Additional Notes

•

0 characters (3500 max)

Screen Shot: DAST -10 Questionnaire

Brief Assessment (DAST-10 questionnaire):

The following questions concern information about your potential involvement with drugs excluding alcohol and tobacco during the past 12 months. Carefully read each question and decide if your answer is "YES" or "NO". Then, check the appropriate box beside the question.

When the words "drug abuse" are used, they mean the use of prescribed or over-the-counter medications used in excess of the directions and any non-medical use of any drugs. Remember that the questions <u>do not</u> include alcohol or tobacco.

Please answer every question. If you have difficulty with a question, then choose the response that is mostly right

These questions refer to the past 12 months.	Yes	No
a) Have you used drugs other than those required for medical reasons?		
b) Do you abuse more than one drug at a time?		
c) Are you always able to stop using drugs when you want to?		
d) Have you had "blackouts" or "flashbacks" as a result of drug use?		
e) Do you every feel bad or guilty about your drug use?		
f) Does your spouse (or parents) ever complain about your involvement with drugs?		
g) Have you neglected your family because of your use of drugs?		
h) Have you engaged in illegal activities in order to obtain drugs?		
i) Have you ever experienced withdrawal symptoms (felt sick) when you stopped taking drugs?		
j) Have you had medical problems as a result of your drug use (e.g., memory loss, hepatitis, convulsions, bleeding, etc.)?		
© Copyright 1982 by Harvey A. Skinner, PhD and the Centre for Addiction and Mental Health, Toronto, Canada, You may reproduce this instrument for non- commercial use (clinical, research, training purposes) as long as you credit the author Dr. Harvey A. Skinner, Dean, Faculty of Health, York University, Toronto,		NE

Canada. Email: harvey.skinner@yorku.ca



Screen Shot: Additional Questions

Drug Type and Frequency of Use Questions:

In the past three months, how often have you used any of the following drugs (do not include medications which you took as prescribed to you)?

Drugs:	Daily or Almost Daily	Weekly /	Monthly or Less Often	Never
Cannabis 🕕	\odot	\odot	\odot	\bigcirc
Cocaine 🐧	\odot	\odot	\odot	\odot
Opioids 🕦	0	\odot	\odot	\odot
Stimulants 🕕	0	\odot	\odot	\odot
Sedatives 🕦	O	O	O	\odot
Other	0	0	0	0
Other	0	0	\odot	\odot
Other	0	0	0	0
Ask about injection drug use: Have you ever used any drug by injection (non-medical use only)?	Yes	No		
If yes, when was the last time you injected?	In the past 90 days	In the past year	Over a year ago	_
Ask about SUD Treatment/Sta	tus:			_
a) Have you ever been in	Yes	No		
treatment for drug abuse?	\odot	\odot		
b) Are you currently in treatment for drug abuse?	Yes	No		
distantion of or or og obuse:	\odot	\odot		
			C	

Provider Assistance Functions

Provider Education

Produce Report of Selected Items

Produce Summary for Patient

Produce a Referral Letter to Doctor

Produce Billing

Produce Visit Note for Session

COMPLETE



Contact Information

Geetha Subramaniam, M.D.

Medical Officer Division of Clinical Neuroscience and Behavioral Research National Institute on Drug Abuse 6001 Executive Boulevard Room 3173, MSC 9593 Bethesda, Maryland 20892-9593

Email: geetha.subramaniam@nih.gov